These targeted therapies have become key components in lung cancer treatment and have demonstrated superiority to chemotherapy in terms of overall response rate (ORR), progression-free survival (PFS), and quality of life in patients with untreated non-small cell lung cancers (NSCLC) with sensitizing EGFR mutations [2–10]. This evidence concerns the gene EGFR and lung cancer.